Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

NCT02925546
Conditions
Heart Failure, Congestive
Interventions
GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Conditions
Renal Impairment, Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Knoxville, Tennessee
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
The Bronx, New York • Nashville, Tennessee • San Antonio, Texas
Recruiting Not applicable Interventional Accepts healthy volunteers

Breath Analysis & Malnutrition

NCT06115148
Conditions
Malnutrition
Interventions
Feeding, Fasting
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Healthy Volunteers
Interventions
MORF-057, Placebo for MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 PK/PD Study

NCT02608710
Conditions
Gout
Interventions
RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Thrombocytopenia
Interventions
avatrombopag
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Completed Phase 1 Interventional Results available

Study of Avelumab-M3814 Combinations

NCT03724890
Conditions
Oncology, Solid Tumors
Interventions
M3814, Avelumab, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Tampa, Florida • Chicago, Illinois • Lake Success, New York + 5 more
Conditions
Nutritional Status
Interventions
GSK1325756
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetic Kidney Disease
Interventions
Selonsertib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Orlando, Florida + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

NCT00775151
Conditions
Healthy
Interventions
amlodipine 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Pharmacokinetics
Interventions
Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Cystic Fibrosis
Interventions
VX-118
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-05175157 In Healthy Volunteers

NCT01274663
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
South Miami, Florida
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Conditions
Critically Ill
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
Up to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Gastroesophageal Reflux
Interventions
rabeprazole sodium
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Psoriasis
Interventions
Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

NCT01499017
Conditions
Healthy
Interventions
PF-06291874 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut